UnknownPhase 2NCT05932524
Low-dose Baricitinib Plus High-dose Dexamethasone for Patients With Newly Diagnosed Immune Thrombocytopenia
Studying Autoimmune thrombocytopenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Peking University People's Hospital
- Principal Investigator
- Xiaohui ZhangPeking University Institute of Hematology, Peking University People's Hospital
- Intervention
- Baricitinib 2 MG(drug)
- Enrollment
- 132 enrolled
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2023 – 2025
Study locations (10)
- Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, China
- Beijing Friendship Hospital, Beijing, China
- Beijing Hospital, Beijing, China
- Beijing Luhe Hospital, Beijing, China
- Beijing Tsinghua Changgeng Hospital, Beijing, China
- China-Japan Friendship Hospital, Beijing, China
- Chinese PLA General Hospital, Beijing, China
- Peking University First Hospital, Beijing, China
- Peking University Third Hospital, Beijing, China
- The Sixth Medical Center of PLA General Hospital, Beijing, China
Collaborators
Beijing Luhe Hospital · Chinese PLA General Hospital · Navy General Hospital, Beijing · Beijing Hospital · Beijing Friendship Hospital · Peking University First Hospital · Peking University Third Hospital · China-Japan Friendship Hospital · Beijing Tsinghua Changgeng Hospital
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05932524 on ClinicalTrials.govOther trials for Autoimmune thrombocytopenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07559331High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune ThrombocytopeniaShandong University
- RECRUITINGPHASE2NCT07362238Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07362199Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGEARLY PHASE1NCT07441525UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE2NCT07234019Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07297563Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07294365A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)Dizal Pharmaceuticals
- RECRUITINGPHASE2NCT07104565Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell DisordersIncyte Corporation